Document Detail


Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.
MedLine Citation:
PMID:  9373264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9; 11)(p22; q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9; 11) group (83% v 43%, P = .006), the patients with t(9; 11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9; 11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46% v 9%, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9; 11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79%) with t(9; 11) and 13 (57%) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9; 11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29%) patients with t(9; 11) remain alive in first CR. Seven of eight patients with t(9; 11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9; 11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9; 11) patients who receive intensive postremission therapy.
Authors:
K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Related Documents :
14584754 - Erythropoietic activities in acute leukemia and in malignant lymphoma with or without b...
10589074 - Acid-base and electrolyte abnormalities in patients with acute leukemia.
53444 - A clinical service for prenatal diagnosis.
9063374 - Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation t...
20561984 - Study of chromosomal region 5p13.1 in crohn's disease, ulcerative colitis, and rheumato...
12379404 - Platelet-monocyte aggregates in patients with chronic venous insufficiency remain eleva...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Blood     Volume:  90     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1997-12-23     Completed Date:  1997-12-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4532-8     Citation Subset:  AIM; IM    
Affiliation:
Roswell Park Cancer Institute, Buffalo, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Chromosome Aberrations
Chromosomes, Human, Pair 11*
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9*
DNA-Binding Proteins / genetics
Humans
Leukemia, Myeloid / genetics*,  physiopathology,  therapy
Myeloid-Lymphoid Leukemia Protein
Proto-Oncogenes*
Remission Induction
Transcription Factors*
Translocation, Genetic*
Treatment Outcome
Zinc Fingers
Grant Support
ID/Acronym/Agency:
CA35279/CA/NCI NIH HHS; CA37027/CA/NCI NIH HHS; CA47545/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/DNA-Binding Proteins; 0/MLL protein, human; 0/Transcription Factors; 149025-06-9/Myeloid-Lymphoid Leukemia Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Next Document:  Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to f...